Mid‐term surgical success after transscleral ab interno glaucoma gel stent implantation
Acta Ophthalmologica · 2024
DOI: 10.1111/aos.16668 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von Markus Lenzhofer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Optometry, Paracelsus Medical University Salzburg, Salzburger Landeskliniken, Salzburg, Austria. Hauptthemen laut MEDLINE: Intraocular Pressure, Glaucoma, Open-Angle, Glaucoma Drainage Implants, Stents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Purpose
To investigate the surgical success and efficacy of XEN45 implantation (XEN45 μm, AbbVie Inc., USA) with and without combined cataract surgery up to the first 5 years.
Methods
In a prospective observational monocentric trial, 192 eyes of 157 patients with open‐angle glaucoma received either XEN45 implants only ( solo surgery group ) or combined surgery/cataract surgeries ( combined surgery group ). Surgical success (qualified and full success; IOP‐limit: ≤12, 15, 18, 21 mmHg), time to secondary IOP‐lowering procedure, IOP and number of IOP‐lowering medications were analysed for 1, 2, 3, 4 and 5 years.
Results
Compared to baseline, IOP (24.1 ± 8.1 to 12.6 ± 2.8 mmHg, −48%, p < 0.001) and the number of IOP‐lowering medications (3.0 ± 1.0 to 1.5 ± 1.2, −50%, p < 0.001) decreased significantly at 5 years. Although no differences between IOP and the number of IOP‐lowering medication courses between the groups were detected at 5 years ( p > 0.11), the combined procedure (63%, 37%) showed better success rates compared to the solo procedure (36%, 13%) in the definition IOP ≤18 and ≤12 mmHg ( p = 0.035, 0.028). Solo XEN45 procedures had a higher rate of secondary IOP‐lowering procedures compared to combined XEN45 cataract procedures (hazard ratio: 2.02, 95%CI: 1.03–3.97, p = 0.04). Twenty per cent of the eyes, including both procedures, required a secondary IOP‐lowering procedure within 5 years.
Conclusions
The XEN45 implant is effective in lowering IOP and the number of IOP‐lowering medications in patients with open‐angle glaucoma in the mid‐term. Comparing XEN45 implant results with the results of trabeculectomy available in current literature, we speculate that there might be a higher surgical success rate without medications in favour of trabeculectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Optometry, Paracelsus Medical University Salzburg, Salzburger Landeskliniken, Salzburg, Austria.
- Research Program Experimental Ophthalmology, Paracelsus Medical University Salzburg, Salzburger Landeskliniken, Salzburg, Austria.
- Research and Innovation Management (RIM), Team Biostatistics and Publication of Clinical Trial Studies/Machine Learning, Paracelsus Medical University Salzburg, Salzburg, Austria.
ORCID-Profile: Markus Lenzhofer, Herbert A Reitsamer
Förderung
- AbbVie
Zitieren
APA
Lenzhofer, M., Hohensinn, M., Steiner, V., Hitzl, W., Runge, C., Trost, A., Colvin, H. P., Brunner, S., Preishuber-Pflügl, J., & Reitsamer, H. A. (2024). Mid‐term surgical success after transscleral ab interno glaucoma gel stent implantation. Acta Ophthalmologica. https://doi.org/10.1111/aos.16668
Vancouver
Lenzhofer M, Hohensinn M, Steiner V, Hitzl W, Runge C, Trost A, et al. Mid‐term surgical success after transscleral ab interno glaucoma gel stent implantation. Acta Ophthalmologica. 2024. doi:10.1111/aos.16668
BibTeX
@article{Lenzhofer2024,
author = {Lenzhofer, Markus and Hohensinn, Melchior and Steiner, Veit and Hitzl, Wolfgang and Runge, Christian and Trost, Andrea and Colvin, Hans Peter and Brunner, Susanne and Preishuber-Pflügl, Julia and Reitsamer, Herbert A},
title = {Mid‐term surgical success after transscleral ab interno glaucoma gel stent implantation},
journal = {Acta Ophthalmologica},
year = {2024},
doi = {10.1111/aos.16668}
}
EUVIMED